120 related articles for article (PubMed ID: 8718500)
1. 3,4-dihydroxyphenylalanine (DOPA) metabolism in screening-detected and non-screening-detected neuroblastoma.
Ikeda H; Suzuki N; Takahashi A; Kuroiwa M; Matsuyama S
Pediatr Hematol Oncol; 1996; 13(1):21-32. PubMed ID: 8718500
[TBL] [Abstract][Full Text] [Related]
2. 3,4-dihydroxyphenylalanine (DOPA) decarboxylase deficiency and resultant high levels of plasma DOPA and dopamine in unfavorable neuroblastoma.
Ikeda H; Matsuyama S; Suzuki N; Takahashi A; Kuroiwa M
Hypertens Res; 1995 Jun; 18 Suppl 1():S209-10. PubMed ID: 8529065
[TBL] [Abstract][Full Text] [Related]
3. 3,4-dihydroxyphenylalanine (dopa) metabolism and retinoic acid induced differentiation in human neuroblastoma.
Ikeda H; Pastuszko A; Ikegaki N; Kennett RH; Wilson DF
Neurochem Res; 1994 Dec; 19(12):1487-94. PubMed ID: 7877718
[TBL] [Abstract][Full Text] [Related]
4. Plasma dopa and catecholamines in the diagnosis and follow-up of children with neuroblastoma.
Alvarado CS; Faraj BA; Kim TH; Camp VM; Bain RP; Ragab AH
Am J Pediatr Hematol Oncol; 1985; 7(3):221-7. PubMed ID: 3934994
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma.
Eldrup E; Clausen N; Scherling B; Schmiegelow K
Scand J Clin Lab Invest; 2001; 61(6):479-90. PubMed ID: 11681538
[TBL] [Abstract][Full Text] [Related]
6. Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma.
Boomsma F; Ausema L; Hakvoort-Cammel FG; Oosterom R; Man in't Veld AJ; Krenning EP; Hahlen K; Schalekamp MA
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1045-52. PubMed ID: 2503383
[TBL] [Abstract][Full Text] [Related]
7. Catecholamine metabolism in neuroblastoma.
LaBrosse EH; Comoy E; Bohuon C; Zucker JM; Schweisguth O
J Natl Cancer Inst; 1976 Sep; 57(3):633-8. PubMed ID: 10450
[TBL] [Abstract][Full Text] [Related]
8. Dopa-release from mouse neuroblastoma clone N 1 E-115 into the culture medium. A test for tyrosine hydroxylase activity.
Bräutigam M; Dreesen R; Herken H
Naunyn Schmiedebergs Arch Pharmacol; 1982 Aug; 320(2):85-9. PubMed ID: 6126821
[TBL] [Abstract][Full Text] [Related]
9. DOPA metabolism in neuroblastoma.
Helson L; Johnson GA; Smith R
Med Pediatr Oncol; 1980; 8(4):317-22. PubMed ID: 6779102
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry DNA ploidy analysis and catecholamine secretion profiles in neuroblastoma.
Abramowsky CR; Taylor SR; Anton AH; Berk AI; Roederer M; Murphy RF
Cancer; 1989 May; 63(9):1752-6. PubMed ID: 2702581
[TBL] [Abstract][Full Text] [Related]
11. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
12. Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion.
de Lonlay P; Simon-Carre A; Ribeiro MJ; Boddaert N; Giurgea I; Laborde K; Bellanné-Chantelot C; Verkarre V; Polak M; Rahier J; Syrota A; Seidenwurm D; Nihoul-Fékété C; Robert JJ; Brunelle F; Jaubert F
J Clin Endocrinol Metab; 2006 Mar; 91(3):933-40. PubMed ID: 16403819
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of catecholamine biosynthesis by carbidopa and metyrosine in neuroblastoma.
Anton AH; Crumrine RS; Stern RC; Izant RJ
Pediatr Pharmacol (New York); 1983; 3(2):107-17. PubMed ID: 6425794
[TBL] [Abstract][Full Text] [Related]
14. L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells.
Pardo B; Mena MA; de Yébenes JG
J Neurochem; 1995 Feb; 64(2):576-82. PubMed ID: 7830050
[TBL] [Abstract][Full Text] [Related]
15. Melanogenesis in cultured human neuroblastomas.
Aubert C; Janiaud P; Rouge F; Hansson C; Rorsman H; Rosengren E
Ann Clin Res; 1980 Dec; 12(6):288-94. PubMed ID: 6786205
[TBL] [Abstract][Full Text] [Related]
16. Adrenomedullary secretion of DOPA, catecholamines, catechol metabolites, and neuropeptides.
Chritton SL; Chinnow SL; Grabau C; Dousa MK; Lucas D; Roddy D; Yaksh TL; Tyce GM
J Neurochem; 1997 Dec; 69(6):2413-20. PubMed ID: 9375673
[TBL] [Abstract][Full Text] [Related]
17. Radioenzymatic assay of DOPA (3,4-dihydroxyphenylalanine).
Johnson GA; Gren JM; Kupiecki R
Clin Chem; 1978 Nov; 24(11):1927-30. PubMed ID: 709823
[TBL] [Abstract][Full Text] [Related]
18. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
19. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
20. Dopa decarboxylase activity of the living human brain.
Gjedde A; Reith J; Dyve S; Léger G; Guttman M; Diksic M; Evans A; Kuwabara H
Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2721-5. PubMed ID: 1688340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
